

## AMENDMENTS TO THE CLAIMS

### Listing of Claims

1-8. (Cancelled)

9. (Currently Amended) A method for inhibiting synovial cell growth, comprising administering to a patient in need thereof a pharmaceutical composition comprising a humanized PM-1 antibody and a physiologically acceptable carrier, wherein said humanized PM-1 antibody comprises

~~(A) — L chain of an antibody to a human IL-6 receptor, comprising the amino acid sequence of SEQ ID NO: 20;~~

~~(B) — H chain of an antibody to the human IL-6 receptor, comprising the amino acid sequence of SEQ ID NO: 18.~~

is an antibody which is humanized by using the complementary determination region of PM-1 deposited as FERM BP-2998 to replace the complementary determination region of a human antibody.

10-12. (Cancelled)

13. (Currently Amended) A method of treating chronic rheumatoid arthritis, comprising administering to a patient in need thereof a pharmaceutical composition comprising humanized PM-1 antibody and a physiologically acceptable carrier, wherein said humanized PM-1 antibody comprises:

~~(A) — L chain of an antibody to a human IL-6 receptor, comprising the amino acid sequence of SEQ ID NO: 20;~~

~~(B) — H chain of an antibody to the human IL-6 receptor, comprising the amino acid sequence of SEQ ID NO: 18.~~

is an antibody which is humanized by using the complementary determination region of PM-1 deposited as FERM BP-2998 to replace the complementary determination region of a human antibody.

14. (Previously Presented) The method according to claim [[13]] 2, wherein the antibody suppresses abnormal growth of synovial cells.

15-25. (Cancelled)

---